This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2000;283:1413.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

With the help of a powerful new technology that reveals which genes are active in different kinds of cells, researchers have discovered that diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma, is actually two biologically distinct diseases with different prognoses. The report appears in the January 27 issue of Nature.

In the study, led by Louis Staudt, MD, PhD, of the National Cancer Institute, researchers used microarrays, or "DNA chips," to measure the activity of more than 18,000 genes, many of which are uniquely expressed in immune B cells. The researchers' analysis revealed two distinct patterns of gene expression in patient specimens that correlated with response to treatment: three fourths of patients whose cancer cells showed one pattern were alive after 5 years, while fewer than one fourth of patients whose cancer cells had the other distinct pattern of gene activity were still . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?